

Before treatment



After 3 syringes

Unretouched photos of a paid JUVÉDERM® XC injectable gel patient. One syringe = 1.0 mL of JUVÉDERM® XC.

These photos are not of a clinical trial subject.

In clinical trials, optimal correction was achieved with 3.2 mL. Results lasted up to 1 year. **Individual results may vary.**

Discuss treatment options with your doctor to see if JUVÉDERM® XC is right for you.

A Brief Description of Indications for Use, Contraindications, Warnings, Precautions, and Adverse Events for JUVÉDERM® Injectable Gel (continued)

Contraindications: JUVÉDERM® injectable gel should not be used in patients who have severe allergies marked by a history of anaphylaxis or history or presence of multiple severe allergies. JUVÉDERM® should not be used in patients with a history of allergies to Gram-positive bacterial proteins. JUVÉDERM® Ultra XC and JUVÉDERM® Ultra Plus XC should not be used in patients with a history of allergies to lidocaine.

Warnings: JUVÉDERM® injectable gel should not be injected into blood vessels. If there is an active inflammatory process or infection at specific injection sites, treatment should be deferred until the underlying process is controlled.

Please see additional important safety information inside.



Download the Treatment Visualizer App

- Shows possible JUVÉDERM® XC treatment areas
- Snap or upload your photo to see potential JUVÉDERM® XC results
- Choose from 3 levels of correction
- Schedule an appointment with your doctor to see if JUVÉDERM® XC is right for you




Scan and get the app now

The Treatment Visualizer App is only available for Apple products (iPad®, iPhone®, and iPod touch®).

Discover the difference
with JUVÉDERM® XC today!



1. Pinsky MA, Thomas JA, Murphy DK, Walker PS; for JUVÉDERM® vs ZYPLAST® Nasolabial Fold Study Group. JUVÉDERM® injectable gel: A multicenter, double-blind, randomized study of safety and effectiveness. *Aesthetic Surg J.* 2008;28(1):17-23.



In clinical trials, optimal correction was achieved with 3.2 mL. Results lasted up to 1 year. **Individual results may vary.**

JUVÉDERM® XC Important Safety Information

JUVÉDERM® injectable gel (including JUVÉDERM® Ultra, JUVÉDERM® Ultra Plus, JUVÉDERM® Ultra XC, and JUVÉDERM® Ultra Plus XC) is indicated for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

Side effects are usually mild to moderate, lasting 7 days or less, and include temporary injection-site reactions such as redness, pain, firmness, swelling, and bumps. JUVÉDERM® is not for people with severe allergies.

For more information, please click on the About Safety link at www.juvederm.com or call the Allergan Product Support line at 1-877-345-5372. JUVÉDERM® injectable gel is available by prescription only.

A Brief Description of Indications for Use, Contraindications, Warnings, Precautions, and Adverse Events for JUVÉDERM® Injectable Gel

Indication: In the United States, JUVÉDERM® injectable gel (including JUVÉDERM® Ultra, JUVÉDERM® Ultra Plus, JUVÉDERM® Ultra XC, and JUVÉDERM® Ultra Plus XC) is indicated for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

Please see additional important safety information on right.

Earn **Brilliant Distinctions®** Program points each time you get a JUVÉDERM® XC treatment

- Redeem your points for big savings
- Receive exclusive offers, special event invitations, and exciting new product information
- Visit www.juvederm.com and fill out a simple form to sign up



Join our rewards program and
start earning today!

The Difference Can Be as Easy as 1, 2, or 3

Discuss treatment options with your doctor to see if JUVÉDERM® XC is right for you.

After **1** syringe

Unretouched photos of paid JUVÉDERM® XC injectable gel patients. One syringe = 1.0 mL of JUVÉDERM® XC.

After **2** syringes

These photos are not of clinical trial subjects.

After **3** syringes

In clinical trials, optimal correction was achieved with 3.2 mL. Results lasted up to 1 year. Individual results may vary.



A Brief Description of Indications for Use, Contraindications, Warnings, Precautions, and Adverse Events for JUVÉDERM® Injectable Gel (continued)

Precautions: The safety of JUVÉDERM® for use during pregnancy, in breastfeeding females, or in patients under 18 years has not been established. The safety and effectiveness of JUVÉDERM® injectable gel for the treatment of areas other than facial wrinkles and folds (such as lips) have not been established in controlled clinical studies. Patients who are using substances that can prolong bleeding, such as aspirin or ibuprofen, as with any injection, may experience increased bruising or bleeding at injection site. Patients should inform their physician

before treatment if they are using these types of substances. As with all skin-injection procedures, there is a risk of infection. JUVÉDERM® should be used with caution in patients on immunosuppressive therapy, or therapy used to decrease the body's immune response, as there may be an increased risk of infection. The safety of JUVÉDERM® in patients with a history of excessive scarring (eg, hypertrophic scarring and keloid formations) and pigmentation disorders has not been studied. If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment with JUVÉDERM® injectable gel, or if JUVÉDERM® is administered

before the skin has healed completely after such a procedure, there is a possible risk of an inflammatory reaction at the treatment site.

Adverse events: The most commonly reported side effects are temporary injection-site redness, swelling, pain/tenderness, firmness, lumps/bumps, and bruising. Most side effects are mild or moderate in nature, and their duration is short lasting (7 days or less).

Important: For full safety information, please visit www.juvederm.com or call Allergan Product Support at 1-877-345-5372.

CAUTION: Rx only.

JUVÉDERM® XC is the first and only FDA-approved HA filler that lasts up to 1 year with 1 treatment.¹

Includes all JUVÉDERM® injectable gel formulations. Most subjects acquired optimal correction at initial treatment.

